Who is sponsoring NCT05629598?

NCT05629598 is sponsored by Angde Biotech Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05629598?

Interventions in NCT05629598: Recombinant human erythropoietin injection, Human erythropoietin injection.

What condition does NCT05629598 study?

NCT05629598 studies Renal Anemia.

Is NCT05629598 still recruiting?

NCT05629598 is currently status unknown. Last updated 29 November 2022.

Last reviewed 2022-11-29 · How we verify

NCT05629598

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .

Status unknown Phase 2 Last updated 29 November 2022

What this trial tests

Phase 2 trial testing Recombinant human erythropoietin injection in Renal Anemia in 150 participants. Status unknown.

Timeline

13 April 2022

Primary endpoint
17 March 2023

16 August 2023

Quick facts

Lead sponsor	Angde Biotech Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	13 April 2022
Primary completion	17 March 2023
Estimated completion	16 August 2023
Sites	1 location across China

Drugs / interventions tested

Recombinant human erythropoietin injection
Human erythropoietin injection — full drug profile →

Conditions studied

Renal Anemia — all drugs for Renal Anemia →

Sponsor

Angde Biotech Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Renal Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to explore the optimal dose and administration of the experimental drug, and to evaluate the safety and efficacy of the drug in patients with renal anemia. Patients with renal anemia on regular dialysis treatment are expected to be enrolled in this study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

PEGylated therapeutics in the clinic.
Gao Y, Joshi M, Zhao Z, Mitragotri S. · · 2024 · cited 133× · PMID 38193121 · DOI 10.1002/btm2.10600

Verify or expand the search:

Other recruiting trials for Renal Anemia

Currently open trials in the same condition.

NCT05970172 — A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease · Phase 3 · recruiting
NCT04899661 — A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Wom · active not recruiting

Other Angde Biotech Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT05295173 — A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） · Phase 3 · completed
NCT04028518 — A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke. · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05629598 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Angde Biotech Pharmaceutical Co., Ltd.
Last refreshed: 29 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05629598.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing